An article appeared in the Business Times of India. Mumbai edition. I was saddened when I read it, especially the last paragraph which is a total condemnation of just what is happening in that country. It is so sad, there is so much potential there. Perhaps we can guide the Biosimilars Industry to take a different path because the dynamics are so totally different from generics....Here is a cut and paste from the last paragraph. The unhealthy legacy of process patents” from today’s Business Standard, Mumbai Edition The rot runs deep. For example, a report of the Parliamentary Committee on Health and Family Welfare found that expert opinions necessary for drug approvals were ghost-written by the companies that had sought the approvals. Reports sent in by different experts on the same drug were found to be exact copies of each other, with the same errors! The report said there was “ample evidence” to suggest that these expert opinions were “actually written by the invisible hand of the drug companies and experts merely obliged by putting their signatures”. To raise regulatory standards in the sector, the industry has proposed that India should become a member of the Pharmaceutical Inspection Convention, an association of drug regulators who agree to stick to certain standards. It is estimated that it will take India five years to raise its regulatory ecosystem to that level.
Posted on: Sat, 15 Jun 2013 08:16:28 +0000
Trending Topics
Recently Viewed Topics
© 2015